Mounjaro®
Starting from £179.99/mo
Start journey Learn moreMost people notice very little weight loss in their first week on Mounjaro. That is not a flaw in the medicine — it is by design. The 2.5mg starting dose exists to let your body adjust, not to deliver rapid fat loss, and the clinical trials that showed up to around 21% average body-weight reduction at 15mg were measured over 72 weeks, not seven days. For the week-one picture, what matters most is how the medicine settles, not what the scales say. Mounjaro (tirzepatide) is a prescription-only medicine; a GPhC-registered prescriber decides whether it is clinically suitable for you before any treatment begins.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Tirzepatide activates two gut-hormone receptors (GIP and GLP-1) that together slow stomach emptying, increase the feeling of fullness and signal your brain to want less food. Those effects begin with the very first dose. What does not begin immediately is meaningful fat loss: the body needs weeks of sustained calorie reduction before that shows up reliably on the scales.
The 2.5mg pen you receive at the start of treatment contains four weekly doses. When it arrives (tracked by DPD, in a plain unbranded box) the pen itself is a compact pre-filled device; you do not need to measure anything. The first injection, in the abdomen, thigh or upper arm, is often described by patients as almost anticlimactic in terms of how it feels. What some people notice in the following day or two is different: a quietening of background hunger that many describe as the most striking early change.
Detailed notes on the practical side of your first week on Mounjaro cover injection technique, storage and what to watch for, and are worth reading before you begin.
If the scales move at all in week one, a drop of roughly 0.5–2 kg is within normal range for most people. Some see nothing; a small number see a little more. Interpreting this matters: early movement often reflects reduced food and fluid intake rather than direct fat metabolism. Swings of a kilogram day to day are normal and say nothing meaningful about how well the medicine is working.
The SURMOUNT-1 trial, published in the New England Journal of Medicine, reported average body-weight reductions of around 20–21% at the 15mg dose over 72 weeks, that is the timeframe the evidence is built around, not the first seven days. The NHS tirzepatide information page confirms that results build over months with continued treatment and lifestyle changes alongside.
For a sense of how progress typically unfolds across the first month, our four-week results page gives a more representative early benchmark.
Gastrointestinal effects are the most common early experience: nausea, loose stools, indigestion or a general unsettled stomach. These tend to show up a day or so after the injection and often settle by the end of the week. Not everyone gets them. Mild fatigue and headache also appear in some people during the first few days. None of this means the medicine is not working, it means your digestive system is responding to a mechanism it has not encountered before.
Eating smaller meals, avoiding very fatty food and staying hydrated all help. The tolerability dose is 2.5mg precisely because higher doses produce more pronounced GI effects; starting low reduces the chance of an unpleasant first experience.
What does warrant prompt medical attention: severe, persistent abdominal pain, particularly pain that radiates to the back, which can be a sign of acute pancreatitis. This is uncommon but taken seriously, the MHRA flagged it in a Drug Safety Update in January 2026. Yellow Card at yellowcard.mhra.gov.uk is where suspected side effects can be reported. If you are ever uncertain about a symptom, contact a clinician rather than waiting.
For most people, the meaningful shift begins from weeks four to eight as the dose increases and the appetite suppression becomes more consistent. By week eight, those who are tolerating the medicine well and staying with the lifestyle changes alongside it typically see a clearer trend. The week-by-week results breakdown maps this progression in more detail, and our eight-week results page picks up where the early weeks leave off.
A useful framing: in the first week, success looks like tolerating the medicine comfortably and noticing even a small shift in appetite. That is a positive sign. The number on the scales in week one is a poor predictor of where you end up at week 72.
If you are considering starting treatment and want to understand how the prescribing process works, our Mounjaro overview covers eligibility, the licensed schedule and what the consultation involves. Questions about the cost of private treatment sit on our Mounjaro cost page. When you are ready to take the next step, speak to our prescribers, a GPhC-registered clinician reviews every consultation the same day.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.